PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 2013 June 3; 123(6): 2464–2474.
Published online 2013 May 1. doi:  10.1172/JCI60945
PMCID: PMC3668833

Plasmacytoid dendritic cells promote rotavirus-induced human and murine B cell responses

Abstract

B cell–dependent immunity to rotavirus, an important intestinal pathogen, plays a significant role in viral clearance and protects against reinfection. Human in vitro and murine in vivo models of rotavirus infection were used to delineate the role of primary plasmacytoid DCs (pDCs) in initiating B cell responses. Human pDCs were necessary and sufficient for B cell activation induced by rotavirus. Type I IFN recognition by B cells was essential for rotavirus-mediated B cell activation in vitro and murine pDCs and IFN-α/β–mediated B cell activation after in vivo intestinal rotavirus infection. Furthermore, rotavirus-specific serum and mucosal antibody responses were defective in mice lacking functional pDCs at the time of infection. These data demonstrate that optimal B cell activation and virus-specific antibody secretion following mucosal infection were a direct result of pDC-derived type I IFN. Importantly, viral shedding significantly increased in pDC-deficient mice, suggesting that pDC-dependent antibody production influences viral clearance. Thus, mucosal pDCs critically influence the course of rotavirus infection through rotavirus recognition and subsequent IFN production and display powerful adjuvant properties to initiate and enhance humoral immunity.

Introduction

Humoral immunity provides a critical line of defense against microbial infection at mucosal surfaces. Within the intestine, the largest mucosal surface, secretory IgA is the most abundant antibody under steady-state conditions (1). T cell–dependent IgA induction occurs in response to many infectious agents and requires affinity maturation within germinal centers. Conversely, T cell–independent class switch leads primarily to production of low-affinity antibodies against commensal intestinal bacteria (25). Both mechanisms of IgA induction are critical to the maintenance of gut integrity, as mice deficient in the machinery of class switching to IgA or somatic hypermutation suffer from mucosal infections and hyperplasia in mesenteric LNs (MLN) and Peyer’s patches (6, 7).

Plasmacytoid DCs (pDCs) are crucial first responders to viral infection due to their ability to rapidly induce type I IFN upon recognition of virally encoded molecular patterns, such as single-stranded RNA or DNA (8, 9). The resulting type I IFN response affects viral replication while simultaneously activating diverse immune effector cells (10). Specific ablation of pDCs during viral infection significantly diminishes the early type I IFN response (1114). During herpes simplex-1 and vesicular stomatitis virus infection, pDC depletion impairs CD8+ T cell immunity (12, 15); similarly, during murine cytomegalovirus infection, the absence of pDCs results in diminished activation of early, nonspecific NK cells (12). pDCs can also activate B cells and induce antibody class switch through type I IFN (1619). These studies, however, involved CD40 engagement on the B cell as a secondary stimulus. Microbiota-triggered type I IFN derived from intestinal stromal epithelial cells acts on pDCs to induce IgA during steady state (20). However, the mechanisms governing optimal induction of mucosal antigen–specific IgA responses to viral infection and the role of pDCs in this setting remain unclear.

We have recently demonstrated that stimulation of purified primary human pDCs with rotavirus (RV), an important intestinal pathogen in humans and many animals, directly induces secretion of cytokines, including large amounts of type I IFN (21). Additional studies demonstrate that lymphoid, but not epithelial, cells produce the majority of intestinal type I IFN after in vivo RV infection (22). As such, we sought to determine whether pDCs directly contribute to B cell activation and subsequent virus-specific antibody production, using both the human in vitro and murine in vivo models of RV infection. B cells represent an important component of the protective immune response against RV: mice deficient in B cells are susceptible to reinfection as adults (23), and antibodies, but not T cells, mediate long-term protection from reinfection (2427). Additionally, RV-specific serum antibodies are sufficient to suppress RV antigenemia in the absence of T cells (28), and transfer of B cells is sufficient to effect RV clearance in chronically infected Rag-knockout mice (29). Passive transfer of highly purified human IgM memory B cells into NOD/Shi-SCID IL-2Rγnull immunodeficient mice suppresses systemic RV viremia, but not fecal shedding (30). In vivo RV infection results in early and substantial B cell activation (3133), which is also observed following in vitro RV infection of human PBMCs (34). This activation requires the presence of accessory cells; purification of human B cells prior to infection completely abrogates this response (34). These effects are likely mediated by an innate cell, as comparable levels of B cell activation are observed in wild-type and T cell receptor–deficient mice (31). We hypothesize that pDCs mediate RV-associated B cell activation and antigen-specific maturation and facilitate class switch, thus enhancing enteric clearance of RV infection.

Results

pDCs are necessary and sufficient for human B cell activation by RV in vitro.

RV infection triggers early and substantial B cell activation in vivo (31). We have previously demonstrated that human B cells become activated, as evidenced by CD69 expression, following RV infection of total PBMCs and that this activation is abrogated upon B cell purification (34). Although pDCs perform several important antiviral functions in vivo, other cells, including macrophages and myeloid DCs (35), can also secrete type I IFN in response to infection. We first assessed whether pDCs are required for in vitro B cell activation in response to RV. Human B cells within PBMC preparations depleted of pDCs failed to upregulate the early activation marker CD69 in response to in vitro RV stimulus (Figure (Figure1A).1A). The observed lack of B cell activation was not due to the selection procedure, as reconstitution of the cultures with purified autologous pDCs restored CD69 upregulation so that it was comparable to the levels reached in whole PBMC cultures (Figure (Figure1A).1A). Together, these experiments show that pDCs are necessary for B cell activation by RV in vitro.

Figure 1
pDCs mediate human B cell activation and plasmablast induction by RV in vitro.

To elucidate whether pDCs directly mediate B cell activation in response to RV, we purified human B cells from PBMCs and infected them with RV in the presence or absence of autologous pDCs. We assessed B cell activation, as measured by CD69 expression 12 hours after infection (Figure (Figure1B). In1B). In agreement with previous reports (34), RV infection of purified B cells alone did not result in CD69 upregulation. In the presence of pDCs, however, we observed a significant increase in the percentage of cells expressing CD69 (Figure (Figure1B).1B). This activation was only observed in the presence of both pDCs and RV, indicating the specificity of the response. We conclude that pDCs are sufficient for in vitro human B cell activation by RV.

We have previously shown that RV induces B cells within total PBMCs, but not in isolation, to differentiate into antibody-secreting cells (ASCs) (34). The failure of purified B cells to differentiate into ASCs suggested that other cells participate in this process (34). To determine whether pDCs were required, we assayed total PBMCs or PBMCs depleted of pDCs for plasmablast induction 4 and 5 days after exposure to RV or mock stimulus (Figure (Figure1C).1C). Compared with total PBMC cultures, the percentage of CD3-CD19+CD20loCD38hi plasmablasts was significantly decreased in total PBMC cultures depleted of pDCs both 4 and 5 days after RV stimulus (P < 0.05; repeated measures ANOVA with Neuman-Keuls multiple comparison test). Although the percentage of B cells expressing extracellular IgA was significantly decreased in the absence of pDCs (Figure (Figure1D;1D; P < 0.05; paired t test), surface and intracellular IgM, IgA, and IgG staining among the plasma cells that did form after RV stimulus was similar to that seen on plasma cells within total PBMCs exposed to RV (data not shown), suggesting that the plasma cells that formed in the absence of pDCs retained full functionality. These data demonstrate that pDCs are also necessary for the induction of human plasmablasts following RV stimulus in vitro.

While B cells represent approximately 10% of the circulating PBMC population, pDCs are exceedingly rare, composing approximately 0.1% of total PBMCs (36). Additionally, pDCs predominately reside within the T cell–rich zones of the LN (37). Thus, in vitro coculture of pDCs and B cells may lead to pDC concentrations and cell-to-cell contact formations, greatly overrepresenting the frequency of these events in vivo. To this end, we sought to determine the minimal pDC–to–B cell ratio required for B cell activation in vitro in response to RV exposure. We titrated pDCs into B cell cultures at half-log increments and assessed CD69 expression after overnight culture when stimulated with RV or medium alone. These studies revealed that a very low pDC/B cell ratio (0.0048), equating to approximately 1 pDC per 200 B cells, was sufficient to induce modest but significant increases in the percentage of B cells expressing CD69 (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI60945DS1). Activation was further increased and maximized when we cultured cells at a ratio of 1 pDC per 42 B cells, which approximates the naturally occurring ratio observed in PBMCs (mean: 1 pDC per 30.3 B cells, n = 4; Supplemental Figure 1). Thus, maximal pDC-mediated B cell activation in vitro by RV occurs at physiologically relevant pDC/B cell ratios.

pDCs mediate human B cell activation by soluble type I IFN.

The observed sufficiency of low pDC-to-B cell ratios suggest that B cell activation may depend on a soluble factor secreted by RV-stimulated pDCs rather than on cell-to cell contact. To examine this hypothesis, we performed Transwell experiments in which we plated previously RV-exposed pDCs and B cells together or in separate chambers of the Transwell devices (Figure (Figure2A).2A). RV inoculation of B cells alone was insufficient to induce B cell activation. Likewise, the presence of pDCs in the absence of virus did not induce B cell activation. Importantly, RV-stimulated pDCs activated B cells regardless of whether pDCs were in direct contact with B cells or separated by the Transwell (Figure (Figure2A).2A). Thus, RV-stimulated pDCs effect B cell activation through a soluble factor.

Figure 2
pDCs mediate human B cell activation by soluble type I IFN.

To confirm this observation, we harvested supernatants from pDCs following exposure to RV or mock stimulus. Supernatants from RV-stimulated, but not mock-stimulated, pDCs were sufficient to activate autologous or allogenic B cells following overnight culture (Figure (Figure2B).2B). Activation of B cells following addition of a 1:20 dilution of supernatant from RV-stimulated pDCs suggested that RV potently induced the factor that mediates human B cell activation in pDCs.

Although pDC-derived B cell–activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) have been demonstrated to affect B cell responses, direct pDC/B cell contact was required for this effect (20). We sought to determine whether RV induced BAFF or APRIL expression by pDCs and whether such expression was required to induce the B cell activation phenotype. Approximately 5% of pDCs expressed detectable BAFF at 12 hours post RV infection (hpi), and we observed similar expression of APRIL (Supplemental Figure 2). However, neither BAFF nor APRIL was detectable in supernatants from RV-stimulated primary human pDCs at 6 or 12 hpi (data not shown). Since cell contact is dispensable for B cell activation in our system (Figure (Figure2A),2A), these observations suggest that pDCs mediate the B cell response to RV through factors other than BAFF or APRIL.

pDCs secrete at least 10 cytokines and chemokines, including IFN-α and IFN-β, in response to RV stimulus (Table (Table1,1, adapted from ref. 21). Thus, we sought to determine whether one or more of these secreted factors was responsible for B cell activation by RV. We cultured purified B cells with supernatants from RV- or mock-stimulated pDCs in the presence or absence of neutralizing anti-cytokine/chemokine antibodies or the appropriate isotype controls. As illustrated in Figure Figure2C,2C, CD69 expression by B cells exposed to supernatants from RV-simulated pDCs decreased significantly (~85%; P = 0.002, repeated measures ANOVA with Tukey’s multiple comparison test) upon culture with a combination of anti–IFN-α (αIFN-α), αIFN-β and αIFN-AR2 (the receptor for type I IFN) neutralizing antibodies (indicated as type I IFN in Figure Figure2C).2C). Incubation with αIFN-α alone also significantly decreased the percentage of CD69+ B cells (23%, P = 0.002, repeated measures ANOVA with Tukey’s multiple comparison test) although to a far lesser extent (P < 0.05, αType 1 IFN vs. αIFN-α alone, repeated measures ANOVA with Tukey’s multiple comparison test). Neutralization of IFN-β alone resulted in a 10% (nonsignificant) decrease in the percentage of CD69+ B cells compared with cells treated with isotype controls. Importantly, maximal inhibition of B cell activation by RV-stimulated pDC supernatants requires neutralization of both IFN-α and IFN-β as well as neutralization of the type I IFN receptor, thus eliminating recognition of all type I IFNs by the B cell. While this demonstrates the partially redundant roles of IFN-α and IFN-β, it may also represent a contribution of IFN-ε, IFN-κ, or IFN-ω, minor type I IFN subtypes that also signal through IFN-AR. Culture with neutralizing αIL-6, αIL-8, αIP-10, αMIP-1α, αMIP-1β, αRANTES, or αTNF-α did not significantly change the percentage of B cells activated (data not shown).

Table 1
Cytokines and chemokines secreted by human pDCs following RV stimulus

To determine whether IFN-α, a major type I IFN subtype, was sufficient to induce B cell activation or whether a minor type I IFN subtype was required, we incubated B cells with IFN-α in concentrations present in supernatants from RV-stimulated pDCs (Table (Table1,1, adapted from ref. 21). Both the percentage of B cells expressing CD69 and the MFI of CD69 on these B cells increased similarly to those of B cells exposed to supernatants from RV-stimulated pDCs or cultured directly with RV-stimulated pDCs (Figure (Figure2D).2D). We observed similar results following B cell stimulus with IFN-β or IFN-ω (Supplemental Figure 3). Thus, all tested individual type I IFNs can mediate in vitro B cell activation. Importantly, intracellular staining of total PBMCs following RV stimulation revealed that production of IFN-α and IFN-β, the major type I IFN subtypes, was selectively observed in the pDC compartment (Figure (Figure3).3).

Figure 3
Identification of IFN-α+ cells following RV infection of total PBMCs.

pDCs and type I IFN signaling contribute to in vivo B cell activation following murine RV infection.

We next sought to determine whether pDCs and/or type I IFN mediated B cell activation during RV infection in vivo. To this end, we depleted C57BL/6 mice of pDCs by i.p. injection with αPDCA-1 (aliases: BST2, CD317) antibody or treated with isotype control antibody, at days –3 and –1 prior to oral infection with wild-type murine RV (Supplemental Figure 4A). Although PDCA-1 is exclusively expressed by pDCs under steady-state conditions, other cell types, including B cells, upregulate this marker in response to type I IFN (38). Thus, we stopped αPDCA-1 antibody treatment before RV infection in order to try to avoid inadvertent depletion of non-pDCs, such as activated B cells. Administration of anti–αPDCA-1 significantly reduced the frequency of pDCs in the gut-associated lymphoid tissue of mock- and RV-infected mice (Supplemental Figure 4, B–D), but did not affect the B cell population (Supplemental Figure 4E).

As previously reported (31), we observed significant increases in B cell activation in the Peyer’s patches and MLN, but not spleen, of infected mice treated with isotype control antibody 3 days after RV infection (Figure (Figure4,4, A and B). αPDCA-1 treatment completely abrogated this increase, resulting in B cell activation comparable to that of uninfected animals (Figure (Figure4,4, A and B). Thus, pDCs appear to regulate B cell activation in the Peyer’s patches and MLNs during in vivo RV infection.

Figure 4
pDCs and type I IFN signaling contribute to in vivo B cell activation following murine RV infection.

To establish whether, as observed for human B cells, type I IFN initiated B cell activation following in vivo RV infection, IFN-α/β receptor (IFN-R) knockout mice or SV129 wild-type controls were infected with murine RV. As shown (Figure (Figure4,4, C and D), elimination of IFN-R signaling fully abrogated B cell activation in Peyer’s patches and MLNs in response to in vivo RV infection. Together, these data demonstrate that mucosal B cell activation requires pDCs and type I IFN signaling during in vivo RV infection.

pDC deficiency impairs in vivo serum and fecal antibody responses to RV.

To further elucidate the consequences of pDC deficiency during in vivo rotaviral infection, we examined RV-specific antibody responses by ELISA. We observed defective RV-specific serum IgG and IgA responses in αPDCA-1–treated mice at 5 and 10 days post infection (dpi), respectively (Figure (Figure5,5, A and B). In contrast, RV-specific IgM titers (Figure (Figure5C)5C) were higher in mice lacking functional pDCs early after infection. Whether the increased IgM reflects a deficit in class switching in the absence of pDCs or is a compensatory response to diminished IgG and IgA is unclear at this point. Importantly, total IgA, IgG, and IgM levels were similar among all groups of animals at 7 and 10 dpi (data not shown), indicating that the defective response was restricted to virus-specific antibody production.

Figure 5
pDC-deficiency impairs in vivo serum antibody responses to RV.

Intestinal IgA is an important component of the resolution of RV infection (3941). As RV-specific antibody responses are observed in T cell receptor–deficient mice (27) and CD8+ T cells accelerate RV clearance (23, 42), we repeated our αPDCA-1 antibody treatment regimen followed by oral RV infection in CD8-deficient animals to assess the role of pDCs in the induction of RV-specific fecal IgA during acute infection independent of the CD8+ T cell response. As observed in the serum, RV-specific fecal IgA production was significantly diminished following infection in αPDCA-1–treated CD8 knockout mice (Figure (Figure6A).6A).

Figure 6
pDC deficiency impairs in vivo mucosal IgA responses to RV.

To ascertain whether induction of the murine B cell response to RV specifically required pDC-derived type I IFN, we next employed an αSiglecH antibody, previously demonstrated to abrogate type I IFN production by pDCs in a DAP12-dependent manner (43). We treated wild-type C57BL6/J with αSiglecH antibody daily, from day –1 prior to infection through 5 dpi, as αSiglecH does not deplete pDCs (ref. 43 and Supplemental Figure 4). Consistent with the αPDCA-1–treated mouse results, a significant defect in B cell activation was also observed in the αSiglecH-treated mice (Supplemental Figure 5). This further demonstrates that pDCs, through type I IFN, mediate B cell activation. Additionally, the deficiency in fecal RV–specific IgA was significantly more pronounced in αSiglecH-treated CD8+ T cell knockout mice (Figure (Figure6A).6A). To confirm these results, and to rule out possible nonspecific effects of the antibody treatment, we used BDCA2-DTR transgenic mice. pDC-depletion in these animals can be selectively induced by diphtheria toxin (DT) injection (12). Consistent with αPDCA-1– and αSiglecH-treated CD8+ T cell knockout mice, shedding of RV-specific IgA was significantly decreased in BDCA2-DTR animals following pDC depletion (Figure (Figure6B).6B). Since the BDCA2-DTR mice contain normal CD8+ T cell numbers, these data show a direct effect of pDCs that is not influenced by any possible side effects created by the lack of CD8+ T cells. Together, these data indicate that pDC-derived type I IFN is essential for the optimal induction of mucosal virus–specific antibody responses in vivo.

The defective pDC response enhances rotaviral shedding.

We next examined the effects of impaired pDC responses on RV replication by examining fecal shedding of RV antigen in adult mice treated with selected anti-pDC antibodies (Figure (Figure7A).7A). As above, we used CD8 knockout mice in these studies, as CD8+ T cells themselves have been demonstrated to enhance RV clearance (23, 42). This approach enabled the direct examination of the pDC-instructed B cell response with regard to rotaviral clearance independent of cytotoxic T lymphocyte effects.

Figure 7
The defective pDC response enhances rotaviral shedding.

Both αPDCA-1– and αSiglecH-treated mice shed increased amounts of RV antigen in the feces compared with isotype-control animals following RV infection (P < 0.02, Figure Figure7A).7A). As expected, this was significantly more pronounced with the continual administration of the αSiglecH antibody compared with the animals treated with αPDCA-1 antibody only prior to infection (P = 0.0011, Figure Figure7A7A and Supplemental Figure 4). Peak viral shedding was observed in αSiglecH- and αPDCA-1–treated mice on 6 dpi, while maximal shedding was observed at 7 dpi in the mice receiving the isotype control (Figure (Figure7A).7A). Furthermore, isotype control–treated mice cleared virus by 8 dpi, at which time RV antigen was still detectable in the feces of αSiglecH- and αPDCA-1–treated animals. Notably, total RV shedding was significantly increased in mice receiving αSiglecH (P = 0.0011, Figure Figure7A).7A). A similar statistically significant prolongation of shedding was observed in IFN-R knockout mice compared with SV129 wild-type mice (P = 0.0152, data not shown). Separate studies performed in BDCA2-DTR animals and their wild-type controls, which both had functional CD8+ T cells, revealed an early enhancement in viral shedding at 3 dpi in the absence of pDCs (Figure (Figure7B).7B). We did not observe differences in viral clearance, presumably due to sufficiently strong CD8+ T cell responses in these mice (data not shown). Together, these data signify that the pDC response is integral to the early control of RV replication and contributes to viral clearance.

Discussion

B cells are critical for the generation of protective immunity to multiple viral infections, including RV. While transfer of either T or B cells to chronically infected Rag-knockout mice is sufficient to mediate RV clearance, suckling JHD (B cell deficient) pups that cleared primary infection with murine RV were susceptible to reinfection as adults (23). Additionally, sporadic shedding has been reported in JHD and μMT mice following initial viral clearance (23, 42). Consistent with these observations, B cell activation is observed in murine gut–associated lymphoid tissues, such as Peyer’s patches and MLN, early following in vivo RV infection (31). This rapid B cell response is T cell independent in mice (32). Recent studies of human circulating and intestinal B cells stimulated with RV in vitro suggest that B cell activation requires an accessory innate cell or molecule (34).

In the present study, we demonstrate that pDCs are necessary and sufficient for activation by RV in both in vitro and in vivo human and murine B cells, respectively. Consistent with previous descriptions of B cell activation during human cytomegalovirus infection (19), type I IFN mediates induction of B cell activation during RV infection. Importantly, and in contrast with previous findings utilizing influenza and human cytomegalovirus, the current study demonstrates that in vitro pDC-mediated early activation of B cells is independent of additional stimuli such as CD40 or B cell receptor ligation (17, 19, 44).

Type I IFN has been demonstrated to upregulate expression of TLR7 and TLR9 by B cells (4547), thus enhancing nucleic acid recognition and B cell responses. As pDC infection by RV is generally not productive (21) and transfer of supernatants alone from RV-stimulated pDCs is sufficient to induce B cell activation in the absence of virus (Figure (Figure2B),2B), direct recognition of RV by B cells appears dispensable for B cell activation in vitro. The present study does not exclude the possibility that recognition of type I IFN upregulates TLRs in the B cell, thus enhancing viral recognition and the B cell response. However, the sufficiency of pDC-conditioned supernatants to induce B cell activation demonstrates that viral recognition by the B cell is not required for this initial activation.

Previous reports demonstrated that type I IFN mediates activation of LN-resident B cells in response to influenza or West Nile virus infection (4851). In the context of West Nile virus infection, the authors excluded macrophages as type I IFN–producing cells, but the actual cellular source was not identified for either infection model. Here, we identify pDCs as the sole type I IFN-α/ β–producing cells in human PBMC cultures following RV stimulus (Figure (Figure3).3). Furthermore, recent studies demonstrate that murine RV infection induces type I IFN production in lymphoid, but not epithelial, cells, bolstering the current findings (22). We have previously shown that primary human pDCs secrete approximately 10,000 pg/ml of both IFN-α and IFN-β when cultured for 6–12 hours at 1 × 106 pDCs/ml after RV stimulus (21). While the minor type I IFN-ω can induce B cell activation (Supplemental Figure 3), the magnitude of the IFN-α/β response, combined with a specific decrease in B cell activation after IFN-α neutralization, implies a minor role for other type I IFN subtypes in this process.

To address pDC-mediated B cell activation in vivo as well as to examine the resulting impact on viral clearance, we employed the mouse model of homologous murine RV infection (41, 52). The absence of pDCs or the defect in the ability of pDCs to effect type I IFN secretion abolished mucosal B cell activation in vivo (Figure (Figure44 and Supplemental Figure 5).

Transient administration of αPDCA-1, as carried out here, only temporarily ablates pDCs (Supplemental Figure 4). Since other cell types, including B cells, upregulate PDCA-1 in response to type I IFN (38), we administered depleting antibody only at days –3 and –1 prior to infection, as previously described (11), to avoid the inadvertent depletion of other cell types that might have upregulated PDCA-1 following an IFN response to RV infection. To further control for a specific effect of pDC depletion on B cell function in response to RV, we employed BDCA2-DTR mice. BDCA2 is a highly specific pDC marker in the human system. The mice we used here carry a transgene consisting of the human BDCA2 promoter coupled to the primate DT receptor. Previous studies have shown that DT injection faithfully depletes only pDCs in this model (12). The use of this alternative approach allows full ablation of the pDC response during the whole time course of infection, since we continually administered DT during the ongoing rotaviral infection and immune response. Additionally, the DT-mediated depletion rules out potential nonspecific effects caused by depleting antibodies. In addition to demonstrating the requirements for pDCs through these complementary methods of pDC depletion, we also probed the role of pDC-dependent type I IFN production using a nondepleting αSiglecH antibody; engagement of SiglecH, a lectin receptor specifically expressed by pDCs and a very small subset of tissue-resident macrophages under steady-state and inflammatory conditions, specifically inhibits type I IFN production by pDCs (refs. 43, 53, and Supplemental Figure 6). Importantly, macrophages within the spleen and gut-associated lymphoid tissues did not costain with αSiglecH antibody by flow cytometry in our hands (data not shown). SiglecH engagement inhibited B cell activation and RV-specific fecal IgA production in our studies, strengthening our human in vitro data in suggesting a crucial role of type IFN in pDC-mediated B cell activation.

Downstream of early activation, we observed defective plasmablast formation in vitro as well as defects in antigen-specific serum and mucosal antibody responses in vivo in the absence of pDC activity (Figures (Figures1,1, ,5,5, and and6).6). The observed decrease in RV-specific serum IgG and IgA and accompanying increase in serum IgM in the absence of a functional pDC response suggest that pDCs may have a role in the induction of class switch after infection. It is important to note that we detected differences only in RV-specific, but not total, antibody levels, in the αSiglecH- and αPDCA-1–treated animals. Although neither RV clearance nor protection from reinfection requires IgA (29, 54, 55), IgA antibodies against RV structural proteins alone can mediate protection. IgA, but not IgG, monoclonal antibodies administered by a hybridoma “backpack” tumor are sufficient to protect naive newborn mice from primary infection (56), while human RV-specific IgA as well as IgG antibodies are able to neutralize RV in cell culture (25). Additionally, RV-specific IgA but not IgG can confer resistance to infection by neutralizing virus intracellularly following transcytosis (40, 57, 58), and RV-specific serum IgA levels predict protection against severe clinical disease (59).

Our data provide, to the best of our knowledge, the first demonstration that pDCs, as well as pDC-derived type I IFN, contribute to the induction of virus-specific mucosal IgA antibody production and that the absence of this contribution impedes the resolution of RV infection. Although we did not address the effect of pDC-mediated B cell activation on later stages of functional B cell responses in this study, type I IFN has previously been implicated in antibody production at multiple stages, including modulation of plasma cell formation and antibody class switching (17, 49, 60). Additionally, type I IFN is required for the formation of germinal centers in adenovirus infection (61).

While a recent study has demonstrated that pDCs modulate mucosal IgA production in the steady state (20), this was shown to require recognition of pDC-derived BAFF or APRIL by B cells through direct pDC/B cell contact. Importantly, production of type I IFN by stromal cells was essential for the induction of BAFF and APRIL expression by pDCs (20). Our findings extend these steady-state observations, as the present data demonstrate that viral stimulus of pDCs overcomes the need for extrinsic epithelial cell–derived type I IFN for induction of antigen-specific IgA responses. As pDCs rapidly secrete large quantities of type I IFN in response to RV stimulus (21), we performed in vitro studies to examine whether such stimulus was sufficient for the induction of BAFF or APRIL expression by purified human pDCs. The demonstration that RV stimulus induces BAFF and APRIL production, but not secretion, by pDCs (Supplemental Figure 2 and data not shown) combined with the dispensability for pDC/B cell contact for the induction of the B cell response (Figure (Figure2A)2A) indicates that these cytokines are not likely to contribute to the observed in vitro B cell activation. The induction of BAFF and APRIL by pDC-derived type I IFN, independent of stromal cells, would ensure the availability of these ligands for recognition by B cells and thus allow for their contribution to the induction of the mucosal IgA response. As Peyer’s patch–resident pDCs do not efficiently secrete type I IFN (62), we hypothesize that pDCs within the lamina propria or MLN are critical for the induction of the B cell response. Previous studies in suckling mice demonstrated the presence of RV within MLNs during acute infection (63). Furthermore, it has been demonstrated that lymphoid, but not epithelial, intestinal cells produce type I IFN in response to RV infection (22). Studies are currently underway to further elucidate the mechanisms governing this process.

The induction of an anti-RV antibody response can mediate viral clearance and is critically responsible for preventing reinfection (23). The rapid initiation of the pDC type I IFN response by RV appears to accelerate this process as part of the host defense mechanism (Figure (Figure7).7). This is evidenced by increased viral shedding early after infection of αPDCA-1– or αSiglecH-treated mice as well as in the BDCA2-DTR model. Although CD8+ T cells enhance the timely clearance of rotaviral infection and T cells alone can mediate short-term partial protection against RV, RV-induced early B cell activation is T cell independent (31). We thus assessed the role of pDC-mediated B cell responses in the absence of CD8+ T cells. As such, we were able to eliminate the role of cytotoxic T lymphocyte responses in the induction of mucosal antibody production and, importantly, in primary viral clearance (Figure (Figure6A6A and Figure Figure7A).7A). Of note, however, we also saw significant defects in RV-specific fecal IgA and, to a lesser degree, in viral shedding in pDC-deficient BDCA2-DTR animals with an intact CD8+ T cell pool (Figure (Figure6B6B and Figure Figure7B).7B). Restoration of the pDC population after transient αPDCA-1–mediated depletion (Supplemental Figure 4) may have contributed to the more rapid clearance of RV infection and prevented viral shedding and replication from reaching the magnitude observed in αSiglecH-treated animals. Similarly, the intact CD8+ T cell response in BDCA2-DTR mice likely contributed to the timely resolution of RV shedding in these mice, thus causing kinetics of clearance similar to those observed in wild-type animals (Figure (Figure7B7B and data not shown). Importantly, defects in the RV-specific fecal IgA response were observed in the CD8-replete BDCA2-DTR animals as they were in the αPDCA and αSiglecH-treated mice (Figure (Figure6B),6B), thus supporting the critical role of pDCs in this local IgA response.

To the best of our knowledge, the current work demonstrates for the first time the critical requirement of pDC-derived type I IFN for the initiation of both B cell activation and the optimal initiation of mucosal and systemic antigen-specific antibody responses to a viral infection. Importantly, our studies demonstrate that pDCs stimulated with RV have powerful adjuvant properties for B cell activation in vitro and in vivo. In our mouse model of homologous murine RV infection, this allows for potent antibody production and influences viral clearance efficiency. Given the lack of functional differences in response to other systemically administered viruses in pDC-deficient models, we suggest that our findings on the role of pDCs in the modulation of B cell responses, summarized in Figure Figure8,8, may be specifically relevant to mucosal tissues. We have not investigated whether pDC ablation has consequences beyond the B cell response or whether murine pDCs vary in their response to homologous versus heterologous (nonmurine) RV strains. We chose to use a homologous murine RV model because it was only with such a model that the modulating effects on viral replication by pDCs could be fully assessed. If the effects of pDCs on B cell responses are conserved during heterologous infection, type I IFN production by pDCs exposed to future heterologous RV vaccine candidates may serve as a predictive marker to measure their capacity to induce an optimal adaptive immune response in the gut. Since the humoral immune response at mucosal sites is a critical defense barrier for many opportunistic infections, pDC-mediated B cell activation may be a key component of protective immunity to mucosal pathogens.

Figure 8
Model of B cell activation in response to RV.

Methods

Virus preparation and inactivation.

Simian tissue-culture adapted RV (RRV) was grown in fetal monkey kidney (MA104) cells in the presence of trypsin as previously described (64, 65). Virus was trypsin activated (5 μg/ml) at 37°C for 20–30 minutes prior to pDC or B cell infection. All preparations were endotoxin-free, as determined by Limulus amebocyte lysate test (Charles River). RRV preparations were titrated by plaque assay on MA104 cells and expressed as number of PFU/ml, as described (65). The virulent wild-type, non–cell-culture–adapted murine RV strain ECw was used to infect mice. This virus causes diarrhea in 100% of 5-day-old suckling mice, which lasts for approximately 7–9 days (52). The virus was propagated in suckling mice, used as a clarified intestinal homogenate, and its 50% diarrhea dose (DD50) was determined as previously described (52).

Isolation of primary human pDCs and B cells.

PBMCs were isolated from anonymized leukoreduction chambers obtained from the Stanford Blood Center by centrifugation over Ficoll-Hypaque (GE Healthcare). pDCs were negatively selected using the pDC Isolation Kit (Miltenyi Biotec), according to the manufacturer’s instructions. To increase the purity of the pDC preparations, consecutive purifications were performed using an AutoMACS Pro (Miltenyi Biotec). An average of 2 × 106 pDCs, defined as viable, lineage HLA-DR+CD11cCD123+ cells, were isolated per donor; preparations were routinely more than 85% pure. B cells were negatively selected using the human B cell Isolation Kit II and AutoMACS Pro Separator (Miltenyi Biotec), according to the manufacturer’s instructions.

Depletion of pDCs from total human PBMCs.

To ensure complete depletion of pDCs from human PBMCs, pDCs were positively selected by consecutive labeling with CD304 (BDCA4/Neuropilin-1) and CD303 (BDCA2) human microbead kits (Miltenyi Biotec) according to the manufacturer’s instructions. Separation was performed using an AutoMACS Pro Separator. This resulted in more than 98% depletion of the pDC population, as determined by flow cytometry.

Human pDC culture, infection, stimulation, and blocking studies.

Primary human pDCs, B cells, or total PBMCs were exposed to RRV or mock stimulus at a multiplicity of infection of 5 for 1 hour in serum-free RPMI 1640 (CellGro) supplemented with penicillin/streptomycin and l-glutamine (Gibco; Invitrogen). pDCs were present or absent in the B cell and PBMC infections, as indicated. Cells were washed and subsequently cultured at a concentration of 1 × 106 cells/ml in RPMI 1640 with 10% heat-inactivated fetal bovine serum (Hyclone), penicillin/streptomycin, and l-glutamine until harvest.

Human pDC and B cell Transwell cultures.

pDCs and B cells were isolated from PBMCs as described above. Each cell type was exposed to RRV (multiplicity of infection 5) in isolation for 1 hour in serum-free medium prior to plating. Cells were washed and resuspended at a concentration of 1 × 106 cells/ml in RPMI 1640 with 10% heat-inactivated fetal bovine serum, penicillin/streptomycin, and l-glutamine. pDCs and B cells were cultured in 12-well plates in the presence or absence of 0.4-μm Transwell inserts (Corning Inc.) at a ratio of 0.4 pDCs per B cell. When applicable, pDCs were plated within the Transwell and B cells in the well.

Cytokine neutralization and stimulus.

B cells were cultured with pDC-conditioned supernatants in the presence or absence of neutralizing polyclonal antibodies against IFN-α, IFN-β, IFN-AR2 (PBL Interferon Source), MIP-1α, MIP-1β, IP-10, RANTES, TNF-α, IL-6, IL-8, or the isotype controls, normal goat IgG (R&D Systems Inc.), or normal sheep serum (Jackson ImmunoResearch Laboratories) at a concentration of 1 × 106 B cells/ml in RPMI 1640 with 10% heat-inactivated fetal bovine serum, penicillin/streptomycin, and l-glutamine overnight until harvest. Where indicated, purified B cells were cultured with IFN-β or IFN-ω (Pestka Biomedical Laboratories Inc.).

Plasmablast induction.

Total human PBMCs or those depleted of pDCs were cultured for 4 or 5 days in 12-well plates at a concentration of 2 × 106 cells/ml in RPMI 1640 with 10% heat-inactivated fetal bovine serum, penicillin/streptomycin, and l-glutamine after exposure to RRV or mock stimulus, as described above. CpG 2006 (3 μg/ml; Invivogen) and IL-2 (10 ng/ml) were added to mock-stimulated cultures, as indicated, as a positive control for plasmablast induction. After culture, cells were washed and stained for analysis by flow cytometry.

Flow cytometry (FACS).

Supernatants were harvested by centrifugation of cultured pDCs, B cells, or PBMCs, which were then washed once with PBS (CellGro). The LIVE/DEAD Aqua Dead Cell Stain Kit (Invitrogen) was utilized to assess cellular viability via amine exclusion. Surface staining was performed using antibodies against human CD3, CD14, CD16, CD27, CD38, HLA-DR, CD69, CD123 (BD Biosciences), CD11c, CD19, CD20 (eBioscience), and BDCA2 and BDCA4 (Miltenyi Biotec); pDCs were defined as being lineage HLA-DR+CD11cCD123+ and costained with BDCA2 and BDCA4 (21). Plasmablasts were defined as CD3CD19+CD20loCD38hi cells (66). Cellular fixation and permeabilization were performed using Cytofix/Cytoperm (BD Biosciences) per the manufacturer’s instructions prior to intracellular staining for IFN-α (BD Biosciences), IFN-β (Antigenix America), BAFF and APRIL (R&D Systems Inc.), IgM, IgG (Jackson ImmunoResearch Laboratories Inc.), or IgA (Miltenyi Biotec). When appropriate, surface immunoglobulins were blocked prior to permeabilization using F(ab′)2 goat anti-human Igs (Jackson ImmunoResearch Laboratories Inc.). Murine lymphocytes isolated from spleens, Peyer’s patches, or MLNs were stained using antibodies against murine CD4, CD8, CD19, CD69, B220 (BD Biosciences), and SiglecH (eBioscience).

Data were acquired using a LSRII cytometer and DIVA software (BD Biosciences); analysis was performed using FlowJo (Treestar Inc).

Detection of secreted cytokines and chemokines.

Supernatants of cultures more than 85% (mean ± SEM: 90.84% ± 0.7499) pure for pDCs were analyzed by ELISA (R&D Systems Inc.) per the manufacturer’s instructions for the presence of BAFF or APRIL. Additional cytokine and chemokine secretion was determined by Luminex using MILLIPLEX MAP (Millipore) or ELISA (Pestka Biomedical Laboratories Inc.) as previously described (21). Murine IFN-α was captured using the monoclonal antibodies RMMA-1 (Pestka Biomedical Laboratories) and F18 (Hycult Biotech Inc.) and detected with polyclonal rabbit αIFN-α (Pestka Biomedical Laboratories Inc).

Mice and infections.

C57BL/6 and B6.129S2-Cd8atm1Mak/J (CD8 knockout) mice were purchased from The Jackson Laboratory. IFN-R knockout and wild-type 129Sv/Ev were obtained from B&K Universal Ltd. BDCA2-DTR mice were provided by Marco Colonna (Washington University, Saint Louis, Missouri, USA). All mice were maintained at the Palo Alto VA Health Care System Veterinarian Medicine Unit. Four- to six-week-old adult mice were orally inoculated with 3 × 103 DD50 of ECw diluted in M199 medium (Gibco; Invitrogen) or M199 medium alone. Mice were sacrificed at the indicated dpi, and serum, Peyer’s patches, MLN, and spleen were collected and lymphocytes isolated as previously described (67). Lymphocytes were maintained in RPMI 1640 with 10% heat-inactivated fetal bovine serum, penicillin/streptomycin, and l-glutamine prior to analysis by flow cytometry.

In vivo pDC depletions.

C57BL/6 mice were injected i.p. with 100 μg functional-grade purified anti–PDCA-1 (Miltenyi Biotec), anti-SiglecH (AbD Serotec), or rat IgG2b isotype control (BioLegend) as previously described (11, 12). Alternatively, BDCA2-DTR mice were injected i.p. with 200 ng DT (Merck) at days –2, –1, and 0 prior to infection and 200 ng every 2 dpi (12).

ELISA.

RV-specific fecal or serum antibody was detected by ELISA as previously described (23), using peroxidase-labeled rat anti-mouse IgM (Southern Biotech) or goat anti-mouse IgA or IgG (Kirkegaard & Perry Laboratories). Total IgA and IgG concentrations were determined by cytometric bead array (BD Biosciences). ELISA to detect RV antigen in the feces was performed as previously described (23).

Statistics.

Mann-Whitney, Wilcoxon signed rank, ANOVA, and 2-tailed t tests were performed using GraphPad Prism (GraphPad Software Inc). P ≤ 0.05 was considered significant. Error bars indicate SEM.

Study approval.

All animal studies were approved by the Stanford Institutional Animal Care Committee. Institutional review board approval was not required for studies involving human cells, as PBMCs were isolated from anonymized leukoreduction chambers obtained from the Stanford Blood Center.

Supplementary Material

Supplemental data:

Acknowledgments

We thank Marco Colonna for the gift of BDCA2-DTR mice. This work was supported by grants from the NIH (R01 AI012362-24 and P30DK56339 to H.B. Greenberg; R01 DK084647 and R37 AI047822 to E.C. Butcher) and VA Merit Review grants to H.B. Greenberg and E.C. Butcher; K. Lahl is supported by the Deutsche Forschungsgemeinschaft (LA 2738/1-1&2) and a research fellowship (3579) from the Crohn’s and Colitis Foundation of America.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2013;123(6):2464–2474. doi:10.1172/JCI60945.

Emily M. Deal’s present address is: BD Biosciences, San Jose, California, USA.

References

1. Macpherson AJ, McCoy KD, Johansen F-E, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol. 2008;1(1):11–22. doi: 10.1038/mi.2007.6. [PubMed] [Cross Ref]
2. Cerutti A, Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity. 2008;28(6):740–750. doi: 10.1016/j.immuni.2008.05.001. [PMC free article] [PubMed] [Cross Ref]
3. Mora J, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science. 2006;314(5802):1157–1160. doi: 10.1126/science.1132742. [PubMed] [Cross Ref]
4. Tezuka H, et al. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature. 2007;448(7156):929–933. doi: 10.1038/nature06033. [PubMed] [Cross Ref]
5. Xu W, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8(3):294–303. doi: 10.1038/ni1434. [PubMed] [Cross Ref]
6. Strugnell RA, Wijburg OLC. The role of secretory antibodies in infection immunity. Nat Rev Immunol. 2010;8(9):656–667. doi: 10.1038/nri2404. [PubMed] [Cross Ref]
7. Wei M, Shinkura R, Doi Y, Maruya M, Fagarasan S, Honjo T. Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol. 2011;12(3):264–270. doi: 10.1038/ni.1991. [PubMed] [Cross Ref]
8. Asselin-Paturel C, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol. 2001;2(12):1144–1150. doi: 10.1038/ni736. [PubMed] [Cross Ref]
9. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8(8):594–606. doi: 10.1038/nri2358. [PubMed] [Cross Ref]
10. Katze MG, He Y, Gale M. Viruses and interferon: a fight for supremacy. Nat Rev Immunol. 2002;2(9):675–687. doi: 10.1038/nri888. [PubMed] [Cross Ref]
11. Lund JM, Linehan MM, Iijima N, Iwasaki A. Cutting edge: Plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J Immunol. 2006;177(11):7510–7514. [PubMed]
12. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity. 2010;33(6):955–966. doi: 10.1016/j.immuni.2010.11.020. [PMC free article] [PubMed] [Cross Ref]
13. Ammann C, Messer R, Peterson K, Hasenkrug K. Lactate dehydrogenase-elevating virus induces systemic lymphocyte activation via TLR7-dependent IFNalpha responses by plasmacytoid dendritic cells. PLoS One. 2009;4(7):e6105. doi: 10.1371/journal.pone.0006105. [PMC free article] [PubMed] [Cross Ref]
14. Smitt J, Rudd B, Lukacs N. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med. 2006;203(5):1153–1159. doi: 10.1084/jem.20052359. [PMC free article] [PubMed] [Cross Ref]
15. Yoneyama M, et al. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med. 2005;202(3):425–435. doi: 10.1084/jem.20041961. [PMC free article] [PubMed] [Cross Ref]
16. Cerutti A, Qiao X, He B. Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol Cell Biol. 2005;83(5):554–562. doi: 10.1111/j.1440-1711.2005.01389.x. [PubMed] [Cross Ref]
17. Jego G, Palucka AK, Blanck J-P, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19(2):225–234. doi: 10.1016/S1074-7613(03)00208-5. [PubMed] [Cross Ref]
18. Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14(4):461–470. doi: 10.1016/S1074-7613(01)00126-1. [PubMed] [Cross Ref]
19. Varani S, et al. Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. J Immunol. 2007;179(11):7767–7776. [PubMed]
20. Tezuka H, et al. Prominent role for plasmacytoid dendritic cells in mucosal T cell-independent IgA induction. Immunity. 2011;34(2):247–257. doi: 10.1016/j.immuni.2011.02.002. [PubMed] [Cross Ref]
21. Deal EM, Jaimes MC, Crawford SE, Estes MK, Greenberg HB. Rotavirus structural proteins and dsRNA are required for the human primary plasmacytoid dendritic cell IFNalpha response. PLoS Pathog. 2010;6(6):e1000931. doi: 10.1371/journal.ppat.1000931. [PMC free article] [PubMed] [Cross Ref]
22. Sen A, et al. Innate immune response to homologous rotavirus infection in the small intestinal villous epithelium at single-cell resolution. Proc Natl Acad Sci U S A. 2012;109(50):20667–20672. doi: 10.1073/pnas.1212188109. [PubMed] [Cross Ref]
23. Franco MA, Greenberg HB. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol. 1995;69(12):7800–7806. [PMC free article] [PubMed]
24. Jayashree S, Bhan MK, Kumar R, Bhandari N, Sazawal S. Protection against neonatal rotavirus infection by breast milk antibodies and trypsin inhibitors. J Med Virol. 1988;26(3):333–338. doi: 10.1002/jmv.1890260313. [PubMed] [Cross Ref]
25. Johansen K, Svensson L. Neutralization of rotavirus and recognition of immunologically important epitopes on VP4 and VP7 by human IgA. Arch Virol. 1997;142(7):1491–1498. doi: 10.1007/s007050050175. [PubMed] [Cross Ref]
26. Ruggeri FM, Greenberg HB. Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture. J Virol. 1991;65(5):2211–2219. [PMC free article] [PubMed]
27. Franco MA, Tin C, Greenberg HB. CD8+ T cells can mediate almost complete short-term and partial long-term immunity to rotavirus in mice. J Virol. 1997;71(5):4165–4170. [PMC free article] [PubMed]
28. Marcelin G, Miller AD, Blutt SE, Conner ME. Immune mediators of rotavirus antigenemia clearance in mice. J Virol. 2011;85(15):7937–7941. doi: 10.1128/JVI.00844-10. [PMC free article] [PubMed] [Cross Ref]
29. Kuklin N, et al. Protective intestinal anti-rotavirus B cell immunity is dependent on alpha 4 beta 7 integrin expression but does not require IgA antibody production. J Immunol. 2001;166(3):1894–1902. [PubMed]
30. Narvaez CF, et al. Human rotavirus specific IgM memory B cells have differential cloning efficiency and switch capactiy and play a role in antiviral immunity in vivo. J Virol. 2012;86(19):10829–10840. doi: 10.1128/JVI.01466-12. [PMC free article] [PubMed] [Cross Ref]
31. Blutt SE, Warfield KL, Lewis DE, Conner ME. Early response to rotavirus infection involves massive B cell activation. J Immunol. 2002;168(11):5716–5721. [PubMed]
32. Blutt SE, Crawford S, Warfield KL, Lewis DE, Estes MK, Conner ME. The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. J Virol. 2004;78(13):6974–6981. doi: 10.1128/JVI.78.13.6974-6981.2004. [PMC free article] [PubMed] [Cross Ref]
33. Wang Y, et al. Rotavirus infection alters peripheral T-cell homeostasis in children with acute diarrhea. J Virol. 2007;81(8):3904–3912. doi: 10.1128/JVI.01887-06. [PMC free article] [PubMed] [Cross Ref]
34. Narvaez CF, Franco MA, Angel J, Morton JM, Greenberg HB. Rotavirus differentially infects and polyclonally stimulates human B cells depending on their differentiation state and tissue of origin. J Virol. 2010;84(9):4543–4555. doi: 10.1128/JVI.02550-09. [PMC free article] [PubMed] [Cross Ref]
35. Kumagai Y, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity. 2007;27(2):240–252. doi: 10.1016/j.immuni.2007.07.013. [PubMed] [Cross Ref]
36. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci. 2010;1183:89–103. doi: 10.1111/j.1749-6632.2009.05152.x. [PubMed] [Cross Ref]
37. Siegal FP, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421):1835–1837. doi: 10.1126/science.284.5421.1835. [PubMed] [Cross Ref]
38. Asselin-Paturel C, Brizard G, Pin J-J, Briere F, Trinchieri G. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol. 2003;171(12):6466–6477. [PubMed]
39. Feng N, Burns JW, Bracy L, Greenberg HB. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus. J Virol. 1994;68(12):7766–7773. [PMC free article] [PubMed]
40. Burns JW, Siadat-Pajour M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science. 1996;272(5258):104–107. doi: 10.1126/science.272.5258.104. [PubMed] [Cross Ref]
41. Feng N, Vo PT, Chung D, Vo TV, Hoshino Y, Greenberg HB. Heterotypic protection following oral immunization with live heterologous rotaviruses in a mouse model. J Infect Dis. 1997;175(2):330–341. doi: 10.1093/infdis/175.2.330. [PubMed] [Cross Ref]
42. McNeal MM, Barone KS, Rae MN, Ward RL. Effector functions of antibody and CD8+ cells in resolution of rotavirus infection and protection against reinfection in mice. Virology. 1995;214(2):387–397. doi: 10.1006/viro.1995.0048. [PubMed] [Cross Ref]
43. Blasius AL, Cella M, Maldonado J, Takai T, Colonna M. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood. 2006;107(6):2474–2476. doi: 10.1182/blood-2005-09-3746. [PubMed] [Cross Ref]
44. Poeck H, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B-cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood. 2004;103(8):3058. doi: 10.1182/blood-2003-08-2972. [PubMed] [Cross Ref]
45. Bekeredjian-Ding IB, et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B-cells via type I IFN. J Immunol. 2005;174(7):4043–4050. [PubMed]
46. Green NM, et al. Murine B cell response to TLR7 ligands depends on an IFN-β feedback loop. J Immunol. 2009;183(3):1569–1576. doi: 10.4049/jimmunol.0803899. [PMC free article] [PubMed] [Cross Ref]
47. Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ. Type I interferon receptor controls B cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res Ther. 2009;11(4):R112. doi: 10.1186/ar2771. [PMC free article] [PubMed] [Cross Ref]
48. Chang WL, Coro ES, Rau FC, Xiao Y, Erle DJ, Baumgarth N. Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals. J Immunol. 2007;178(3):1457–1467. [PubMed]
49. Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol. 2006;176(7):4343–4351. [PubMed]
50. Purtha WE, Chachu KA, Virgin HW 4th, Diamond MS. Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J Virol. 2008;82(22):10964–10974. doi: 10.1128/JVI.01646-08. [PMC free article] [PubMed] [Cross Ref]
51. Woods A, et al. Influenza virus-induced type I interferon leads to polyclonal B-cell activation but does not break down B-cell tolerance. J Virol. 2007;81(22):12525–12534. doi: 10.1128/JVI.00839-07. [PMC free article] [PubMed] [Cross Ref]
52. Burns JW, Krishnaney AA, Vo PT, Rouse RV, Anderson LJ, Greenberg HB. Analyses of homologous rotavirus infections in the mouse model. Virology. 1995;207(1):143–153. doi: 10.1006/viro.1995.1060. [PubMed] [Cross Ref]
53. Zhang J, et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood. 2006;107(9):3600–3608. doi: 10.1182/blood-2005-09-3842. [PubMed] [Cross Ref]
54. Bernstein DI, Ziegler JM, Ward RL. Rotavirus fecal IgA antibody response in adults challenged with human rotavirus. J Med Virol. 1986;20(4):297–304. [PubMed]
55. O’Neal CM, Harriman GR, Conner ME. Protection of the villus epithelial cells of the small intestine from rotavirus infection does not require immunoglobulin A. J Virol. 2000;74(9):4102–4109. doi: 10.1128/JVI.74.9.4102-4109.2000. [PMC free article] [PubMed] [Cross Ref]
56. Ruggeri FM, Johansen K, Basile G, Kraehenbuhl J-P, Svensson L. Antirotavirus immunoglobulin a neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. J Virol. 1998;72(4):2708–2714. [PMC free article] [PubMed]
57. Corthesy B, et al. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol. 2006;80(21):10692–10699. doi: 10.1128/JVI.00927-06. [PMC free article] [PubMed] [Cross Ref]
58. Feng N, et al. Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP-specific IgA mAb. J Clin Invest. 2002;109(9):1203–1213. doi: 10.1172/JCI14397. [PMC free article] [PubMed] [Cross Ref]
59. Velazquez FR, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis. 2000;182(6):1602–1609. doi: 10.1086/317619. [PubMed] [Cross Ref]
60. Heer AK, et al. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol. 2007;178(4):2182–2191. [PubMed]
61. Zhu J, Huang X, Yang Y. Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus. J Immunol. 2007;178(6):3505–3510. [PubMed]
62. Contractor N, Louten J, Kim L, Biron CA, Kelsall BL. Cutting edge: Peyer’s patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J Immunol. 2007;179(5):2690–2694. [PubMed]
63. Fenaux M, Cuadras MA, Feng N, Jaimes M, Greenberg HB. Extraintestinal spread and replication of a homologous EC rotavirus strain and a heterologous rhesus rotavirus in BALB/c mice. J Virol. 2006;80(11):5219–5232. doi: 10.1128/JVI.02664-05. [PMC free article] [PubMed] [Cross Ref]
64. Cuadras MA, Feigelstock DA, An S, Greenberg HB. Gene expression pattern in Caco-2 cells following rotavirus infection. J Virol. 2002;76(9):4467–4482. doi: 10.1128/JVI.76.9.4467-4482.2002. [PMC free article] [PubMed] [Cross Ref]
65. Hoshino Y, Wyatt RG, Greenberg HB, Flores J, Kapikian AZ. Serotypic similarity and diversity of rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization. J Infect Dis. 1984;149(5):694–702. doi: 10.1093/infdis/149.5.694. [PubMed] [Cross Ref]
66. Wei C, Jung J, Sanz I. OMIP-003: phenotypic analysis of human memory B cells. Cytometry A. 2011;79(11):894–896. [PMC free article] [PubMed]
67. Warfield KL, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol. 2005;175(2):1184–1191. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation